Seelos Therapeutics, Inc. (SEEL)
NASDAQ: SEEL · Real-Time Price · USD
0.292
+0.003 (1.18%)
Aug 30, 2024, 4:00 PM EDT - Market closed
Seelos Therapeutics Revenue
Seelos Therapeutics had revenue of $376.00K in the quarter ending June 30, 2024, with 11.90% growth. This brings the company's revenue in the last twelve months to $2.01M, up 76.05% year-over-year. In the year 2023, Seelos Therapeutics had annual revenue of $2.20M.
Revenue (ttm)
$2.01M
Revenue Growth
+76.05%
P/S Ratio
0.20
Revenue / Employee
$125,875
Employees
16
Market Cap
2.04M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| cbdMD | 20.64M |
| Tenon Medical | 3.37M |
| Tivic Health Systems | 1.11M |
| FOXO Technologies | 155.00K |
| Cyclacel Pharmaceuticals | 80.00K |
| Aclarion | 53.95K |
SEEL News
- 3 months ago - Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules - PRNewsWire
- 3 months ago - Seelos Therapeutics Announces 1-for-8 Reverse Stock Split - PRNewsWire
- 4 months ago - Seelos Therapeutics Announces Strategic Focus on Mental Health Initiatives and Provides an Update on Current Discussions of Potential Partnerships and Collaborations - PRNewsWire
- 5 months ago - Seelos Therapeutics Provides Update on Top-Line Results from its Amyotrophic Lateral Sclerosis (ALS) Study with SLS-005 (IV Trehalose) - PRNewsWire
- 7 months ago - Seelos Therapeutics, Inc. Announces $4.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules - PRNewsWire
- 7 months ago - Seelos Therapeutics Announces Receipt of Minutes from its End of Phase II Meeting with the United States Food and Drug Administration (FDA) Highlighting Modifications to the Primary and Secondary Endpoints of its Phase II Study of SLS-002 - PRNewsWire
- 8 months ago - Leading Independent Proxy Advisory Firm ISS Recommends Seelos Stockholders Vote "FOR" All Proxy Proposals at the Special Meeting to be held on January 10, 2024 - PRNewsWire
- 9 months ago - Seelos Therapeutics, Inc. Releases Letter to its Stockholders - PRNewsWire